{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T01:43:17Z","timestamp":1783388597579,"version":"3.54.6"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-10655-6","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T12:39:45Z","timestamp":1740746385000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Impact of rpoB gene mutations and Rifampicin-resistance levels on treatment outcomes in Rifampicin-resistant tuberculosis"],"prefix":"10.1186","volume":"25","author":[{"given":"Maria","family":"Jose\u00a0Vadakunnel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijayalakshmi Jawaharlal","family":"Nehru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usharani","family":"Brammacharry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkateswari","family":"Ramachandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suganthi","family":"Palavesam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anbazhagi","family":"Muthukumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balasundaram Revathi","family":"Mani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sriramkumar S.","family":"R","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunavathy","family":"Pradhabane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azger Dusthackeer","family":"VN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeetha","family":"Subramani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthuraj","family":"Muthaiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Govindarajan","family":"Soundappan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"10655_CR1","unstructured":"Global Tuberculosis Report. World Health Organization. Available online: https:\/\/www.who.int\/publications\/digital\/globaltuberculosis-report-2021 . Accessed on 23 July 2022."},{"issue":"12","key":"10655_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.943545","volume":"3","author":"D Liebenberg","year":"2022","unstructured":"Liebenberg D, Gordhan BG, Kana BD. Drug resistant tuberculosis: Implications for transmission, diagnosis, and disease management. Front Cell Infect Microbiol. 2022;3(12): 943545.","journal-title":"Front Cell Infect Microbiol"},{"key":"10655_CR3","unstructured":"Global tuberculosis report 2023. Geneva: World Health Organization; 2023. (https:\/\/www.who.int\/tb\/data\/en\/)."},{"issue":"7","key":"10655_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0286194","volume":"18","author":"A Alemu","year":"2023","unstructured":"Alemu A, Bitew ZW, Diriba G, Seid G, Moga S, Abdella S, et al. Poor treatment outcome and associated risk factors among patients with isoniazid mono-resistant tuberculosis: A systematic review and meta-analysis. PLoS ONE. 2023;18(7): e0286194.","journal-title":"PLoS ONE"},{"issue":"12","key":"10655_CR5","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.84815","volume":"3","author":"Y Chen","year":"2023","unstructured":"Chen Y, Jiang Q, Peierdun M, Takiff HE, Gao Q. The mutational signatures of poor treatment outcomes on the drug-susceptible Mycobacterium tuberculosis genome. Elife. 2023;3(12): e84815.","journal-title":"Elife"},{"key":"10655_CR6","doi-asserted-by":"publisher","first-page":"e570","DOI":"10.1016\/S2666-5247(24)00022-3","volume":"5","author":"S Stanley","year":"2024","unstructured":"Stanley S, Spaulding CN, Liu Q, Chase MR, Minh Ha DT, Thai PVK, Lan NH, et al. Identification of bacterial determinants of tuberculosis infection and treatment outcomes: a phenogenomic analysis of clinical strains. Lancet Microbe. 2024;5:e570\u201380.","journal-title":"Lancet Microbe"},{"key":"10655_CR7","doi-asserted-by":"publisher","first-page":"2003300","DOI":"10.1183\/13993003.03300-2020","volume":"57","author":"F Mirzayev","year":"2021","unstructured":"Mirzayev F, Viney K, Linh NN, et al. World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update. Eur Respir J. 2021;57:2003300.","journal-title":"Eur Respir J"},{"issue":"7","key":"10655_CR8","doi-asserted-by":"publisher","first-page":"e0157320","DOI":"10.1128\/AAC.01573-20","volume":"65","author":"WH Lin","year":"2021","unstructured":"Lin WH, Lee WT, Tsai HY, Jou R. Disputed rpoB mutations in mycobacterium tuberculosis and tuberculosis treatment outcomes. Antimicrob Agents Chemother. 2021;65(7):e0157320.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10655_CR9","doi-asserted-by":"publisher","first-page":"1602308","DOI":"10.1183\/13993003.02308-2016","volume":"49","author":"D Falzon","year":"2017","unstructured":"Falzon D, Sch\u00fcnemann HJ, Harausz E, Gonz\u00e1lez-Angulo L, Lienhardt C, Jaramillo E, Weyer K. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J. 2017;49(3):1602308.","journal-title":"Eur Respir J"},{"key":"10655_CR10","unstructured":"The Use of Molecular Line Probe Assays for the Detection of Resistance to Isoniazid and Rifampicin. Policy Update. Geneva: World Health Organization. Available at: https:\/\/www.who.int\/tb\/publications\/molecular-test-resistance\/en\/. Accessed 19 Jan 2019."},{"key":"10655_CR11","unstructured":"GenoType MTBDRplus: Version 2.0 [product insert] Hain Lifescience,304A-01\u201302 GmbH; Nehren, Germany: updated 2016."},{"key":"10655_CR12","doi-asserted-by":"publisher","first-page":"17552","DOI":"10.1038\/s41598-020-74432-y","volume":"10","author":"SS Shivekar","year":"2020","unstructured":"Shivekar SS, Kaliaperumal V, Brammacharry U, et al. Prevalence and factors associated with multidrug-resistant tuberculosis in South India. Sci Rep. 2020;10:17552.","journal-title":"Sci Rep"},{"key":"10655_CR13","doi-asserted-by":"crossref","unstructured":"Mvelase NR, Pillay M, Sibanda W, Ngozo JN,Brust JCM, Mlisana PK. rpoB Mutations Causing Discordant Rifampicin Susceptibility in Mycobacterium tuberculosis: Retrospective Analysis of Prevalence, Phenotypic, Genotypic, and Treatment Outcomes. Open Forum Infect Dis 2019;6(4):ofz065.","DOI":"10.1093\/ofid\/ofz065"},{"issue":"2","key":"10655_CR14","first-page":"1220","volume":"11","author":"A Muthukumar","year":"2024","unstructured":"Muthukumar A, Blasundaram RM, Pradhabane G, Kapalamurthy VC, Brammacharry U, Ramachndra V, Muthaiah M. Access the diagnostic accuracy of genotypic assays for the rapid detection of drug-resistant mycobacterium tuberculosis. J Bacteriol Mycol. 2024;11(2):1220.","journal-title":"J Bacteriol Mycol"},{"key":"10655_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3390\/microbiolres15010006","volume":"15","author":"V Ramachandra","year":"2024","unstructured":"Ramachandra V, Brammacharry U, Muralidhar A, Muthukumar A, Mani R, Muthaiah M, Soundappan G, Frederick A. Assess the Diagnostic Accuracy of GeneXpert to Detect Mycobacterium tuberculosis and Rifampicin-Resistant Tuberculosis among Presumptive Tuberculosis and Presumptive Drug Resistant Tuberculosis Patients. Microbiol Res. 2024;15:91\u2013108.","journal-title":"Microbiol Res"},{"key":"10655_CR16","doi-asserted-by":"publisher","first-page":"19719","DOI":"10.1038\/s41598-024-70535-y","volume":"14","author":"VJ Nehru","year":"2024","unstructured":"Nehru VJ, Jose Vandakunnel M, Brammacharry U, Ramachandra V, Pradhabane G, Mani BR, Azger DVN, Muthaiah M. Risk assessment and transmission of fluoroquinolone resistance in drug-resistant pulmonary tuberculosis: a retrospective genomic epidemiology study. Sci Rep. 2024;14:19719.","journal-title":"Sci Rep"},{"key":"10655_CR17","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.3390\/ijms11072670","volume":"11","author":"M Muthaiah","year":"2010","unstructured":"Muthaiah M, Jagadeesan S, Ayalusamy N, Sreenivasan M, Prabhu SS, Muthuraj U, Senthilkumar K, Veerappan S. Molecular Epidemiological Study of Pyrazinamide-Resistance in Clinical Isolates of Mycobacterium tuberculosis from South India. Int J Mol Sci. 2010;11:2670\u201380.","journal-title":"Int J Mol Sci"},{"key":"10655_CR18","unstructured":"Guidelines for Programmatic Management of Drug-resistant TB in India 2021,National TB Elimination Programme, Central TB Division, Ministry of Health and Family Welfare, Government of India, New Delhi, India."},{"key":"10655_CR19","doi-asserted-by":"publisher","first-page":"2100804","DOI":"10.1183\/13993003.00804-2021","volume":"58","author":"NN Linh","year":"2021","unstructured":"Linh NN, Viney K, Gegia M, et al. World Health Organization treatment outcome definitions for tuberculosis: 2021 update. Eur Respir J. 2021;58:2100804.","journal-title":"Eur Respir J"},{"key":"10655_CR20","unstructured":"MedCalc: MedCalc\u2019s Relative risk calculator. MedCalc Software Ltd, 2024. https:\/\/www.medcalc.org\/calc\/relative_risk.php."},{"key":"10655_CR21","unstructured":"World Health Organization 2022, Line probe assays for detection of drug-resistant tuberculosis: interpretation and reporting manual for laboratory staff and clinicians. https:\/\/www.who.int\/publications\/i\/item\/9789240046665."},{"key":"10655_CR22","first-page":"274","volume":"12","author":"I Cuella-Martin","year":"2023","unstructured":"Cuella-Martin I, Ngabonziza JC, Torrea G, Meehan CJ, Mulders W, Ushizimpumu B, Weerdt LD, Keysers J, De Rijik WB, Decroo T, De Jong BC, Rigouts L. Rifampicin resistance conferring mutations among Mycobacterium tuberculosis strains in Rwanda. Int J Mycobacteriol. 2023;12:274\u201381.","journal-title":"Int J Mycobacteriol"},{"issue":"14","key":"10655_CR23","doi-asserted-by":"publisher","first-page":"4119","DOI":"10.2147\/IDR.S333433","volume":"5","author":"MC Li","year":"2021","unstructured":"Li MC, Lu J, Lu Y, Xiao TY, Liu HC, Lin SQ, Xu D, Li GL, Zhao XQ, Liu ZG, Zhao LL, Wan KL. rpoB Mutations and Effects on Rifampin Resistance in Mycobacterium tuberculosis. Infect Drug Resist. 2021;5(14):4119\u201328.","journal-title":"Infect Drug Resist"},{"issue":"15","key":"10655_CR24","doi-asserted-by":"publisher","first-page":"5655","DOI":"10.2147\/IDR.S375869","volume":"27","author":"HMA Hameed","year":"2022","unstructured":"Hameed HMA, Fang C, Liu Z, Ju Y, Han X, Gao Y, Wang S, Chiwala G, Tan Y, Guan P, Hu J, Xiong X, Peng J, Lin Y, Hussain M, Zhong N, Maslov DA, Cook GM, Liu J, Zhang T. Characterization of Genetic Variants Associated with Rifampicin Resistance Level in Mycobacterium tuberculosis Clinical Isolates Collected in Guangzhou Chest Hospital. China Infect Drug Resist. 2022;27(15):5655\u201366.","journal-title":"China Infect Drug Resist"},{"key":"10655_CR25","first-page":"e01885","volume":"59","author":"J Shea","year":"2020","unstructured":"Shea J, Halse TA, Kohlerschmidt D, et al. Low-level rifampin resistance and rpoB mutations in Mycobacterium tuberculosis: an analysis of whole-genome sequencing and drug susceptibility test data in New York. J Clin Microbiol. 2020;59:e01885-e1920.","journal-title":"J Clin Microbiol"},{"issue":"6","key":"10655_CR26","first-page":"534","volume":"21","author":"D Liu","year":"2021","unstructured":"Liu D, Huang F, Zhang G, et al. Whole-genome sequencing for surveillance of tuberculosis drug resistance and determination of resistance level in China. Clin Microbiol Infect. 2021;21(6):534\u20136.","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"10655_CR27","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.2147\/IDR.S358301","volume":"29","author":"H Xia","year":"2022","unstructured":"Xia H, Song Y, Zheng Y, Wang S, Zhao B, He W, Liu D, Ou X, Zhou Y, Zhao Y. Detection of Mycobacterium tuberculosis Rifampicin Resistance Conferred by Borderline rpoB Mutations: Xpert MTB\/RIF is Superior to Phenotypic Drug Susceptibility Testing. Infect Drug Resist. 2022;29(5):1345\u201352.","journal-title":"Infect Drug Resist"},{"key":"10655_CR28","doi-asserted-by":"publisher","first-page":"2100783","DOI":"10.1183\/13993003.00783-2021","volume":"58","author":"A Van Deun","year":"2021","unstructured":"Van Deun A, Decroo T, Aung KJM, et al. Mycobacterium tuberculosis borderline rpoB mutations: emerging from the unknown. Eur Respir J. 2021;58:2100783.","journal-title":"Eur Respir J"},{"issue":"5","key":"10655_CR29","doi-asserted-by":"publisher","first-page":"e01599","DOI":"10.1128\/JCM.01599-17","volume":"56","author":"P Miotto","year":"2018","unstructured":"Miotto P, Cabibbe AM, Borroni E, Degano M, Cirillo DM. Role of disputed mutations in the rpoB Gene in interpretation of automated liquid MGIT culture results for Rifampin susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol. 2018;56(5):e01599-e1617.","journal-title":"J Clin Microbiol"},{"issue":"9","key":"10655_CR30","doi-asserted-by":"publisher","first-page":"e0274426","DOI":"10.1371\/journal.pone.0274426","volume":"17","author":"M Getahun","year":"2022","unstructured":"Getahun M, Blumberg HM, Ameni G, Beyene D. Kempker RR (2022) Minimum inhibitory concentrations of rifampin and isoniazid among multidrug and isoniazid resistant Mycobacterium tuberculosis in Ethiopia. PLoS ONE. 2022;17(9):e0274426.","journal-title":"PLoS ONE"},{"key":"10655_CR31","doi-asserted-by":"publisher","first-page":"933","DOI":"10.3390\/metabo12100933","volume":"12","author":"F Amalia","year":"2022","unstructured":"Amalia F, Syamsunarno MRAA, Triatin RD, Fatimah SN, Chaidir L, Achmad TH. The Role of Amino Acids in Tuberculosis Infection: A Literature Review. Metabolites. 2022;12:933.","journal-title":"Metabolites"},{"issue":"23","key":"10655_CR32","doi-asserted-by":"publisher","first-page":"100222","DOI":"10.1016\/j.jctube.2021.100222","volume":"29","author":"FA Gopie","year":"2021","unstructured":"Gopie FA, Commiesie E, Baldi S, Kamst M, Kaur D, de Lange WCM, Pinas PS, Stijnberg D, Wongsokarijo M, Zijlmans CWR, de Zwaan R, van Soolingen D, Vreden SGS, de Vries G. Should treatment of low-level rifampicin mono-resistant tuberculosis be different? J Clin Tuberc Other Mycobact Dis. 2021;29(23):100222.","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"10655_CR33","doi-asserted-by":"publisher","first-page":"108980","DOI":"10.1016\/j.biopha.2019.108980","volume":"116","author":"WJ Yi","year":"2019","unstructured":"Yi WJ, Han YS, Wei LL, Shi LY, Huang H, Jiang TT, Li ZB, Chen J, Hu YT, Tu HH, et al. L-Histidine, arachidonic acid, biliverdin, and L-cysteine-glutathione disulfide as potential biomarkers for cured pulmonary tuberculosis. Biomed Pharm. 2019;116:108980.","journal-title":"Biomed Pharm"},{"key":"10655_CR34","doi-asserted-by":"publisher","first-page":"e12394","DOI":"10.1111\/jpi.12394","volume":"62","author":"W Ren","year":"2017","unstructured":"Ren W, Liu G, Chen S, Yin J, Wang J, Tan B, Wu G, Bazer FW, Peng Y, Li T, et al. Melatonin signaling in T cells: Functions and applications. J Pineal Res. 2017;62:e12394.","journal-title":"J Pineal Res"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-10655-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-10655-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-10655-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T12:39:49Z","timestamp":1740746389000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-10655-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10655"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-10655-6","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"assertion":[{"value":"22 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study received ethical approval from the Ethics and Scientific Review Committee of the General Hospital Institute of the Directorate of Health and Family Welfare Services, Pondicherry (No. GHIEC\/2020\/244 ft. 08\u201306-2020), which granted a waiver for informed consent. The research was conducted in strict accordance with the ethical principles of the Helsinki Declaration as outlined by the World Medical Association, and all data were maintained with confidentiality.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"284"}}